WHO Expands Mpox Diagnostics with New Tests

The World Health Organization (WHO) has listed additional mpox diagnostic tests for emergency use. The polymerase chain reaction (PCR) test remains the gold standard. On October 25, WHO listed Xpert Mpox by Cepheid, and Cobas MPXV assay by Roche Molecular Systems was added on October 14, 2024.

The World Health Organization (WHO) has announced the inclusion of new diagnostic tests for mpox to its emergency use list. This move highlights the critical role of PCR testing in identifying mpox infection with precision, as it is considered the gold standard in detection.

On October 25, WHO recognized Xpert Mpox, a real-time PCR test created by the company Cepheid, as a reliable diagnostic tool for mpox infection. This inclusion underscores WHO's commitment to expanding diagnostic capabilities amid health emergencies.

Earlier, on October 14, 2024, WHO listed another PCR-based test, the Cobas MPXV assay, developed by Roche Molecular Systems, Inc. This further broadens the available resources for accurate mpox detection, providing healthcare systems with robust solutions to tackle the disease effectively.

(With inputs from agencies.)